Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
38 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a biotechnology company which develops and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company's pipeline products include Atu027 and Atu111. Its Atu027 is developed for the treatment of pancreatic, head and neck cancer. Silence Therapeutics offers Atu111 for lung indications. The company also develops other products which include PF-655 for diabetic macular edema and wet age related macular degeneration; and QPI 1002 for kidney transplantation and acute kidney injury. It has collaboration with pharmaceutical, biotechnology companies and academic research institutions.

Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals

  
Source:
Document ID
GDPH36126D
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Silence Therapeutics Plc, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Silence Therapeutics Plc, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Silence Therapeutics Plc, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Silence Therapeutics Plc, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Silence Therapeutics Plc, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 201692
Silence Therapeutics Plc, Pharmaceuticals &Healthcare, Deal Details1124
  Partnerships111
    Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies112
    Silence Therapeutics Extends R&D Collaboration With AstraZeneca131
    Silence Therapeutics Extends Co-Development Agreement With AstraZeneca141
    Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma151
  Licensing Agreements161
    Silence Therapeutics Terminates Licensing Agreement With University Of Massachusetts161
  Equity Offering171
    Silence Therapeutics Raises USD59 Million in Private Placement of Shares171
    Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million181
    Silence Therapeutics Completes Private Placement Of Shares For US$29 Million192
    Silence Therapeutics Completes Private Placement Of Shares For US$8 Million212
    Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million232
    Silence Therapeutics Completes Private Placement Of Shares For US$7 Million252
    Silence Therapeutics Announces Private Placement Of Shares For US$16 Million271
    Silence Therapeutics Completes Private Placement Of US$9 Million282
    Silence Therapeutics Completes Public Offering Of US$0.71 Million302
  Acquisition321
    Silence Therapeutics Completes Acquisition Of Intradigm323
Silence Therapeutics Plc - Key Competitors351
Key Employees361
Locations And Subsidiaries371
  Head Office371
  Other Locations &Subsidiaries371
Appendix381
  Methodology381
  About GlobalData381
  Contact Us381
  Disclaimer381

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Silence-Therapeutics-Plc-SLN-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-7593>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Silence-Therapeutics-Plc-SLN-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-7593>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research